Cancer treatment and research communications · 2026
HAVCR2 (TIM-3) as a favorable prognostic immune marker in seminoma: Integrative checkpoint screening and tissue validation.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kim Ki Hong, Lee Dae Young, Yang Hee Jo, Kim Si Hyun, Kim Doo Sang, Lee Chang Ho, Hong Soon Auck, Chi Byung Hoon, Lee Ji-Hye, Jeon Youn Soo
Аннотация
BACKGROUND: Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis have demonstrated limited efficacy in testicular germ cell tumors (TGCTs), highlighting the need to identify alternative immune biomarkers. We evaluated the prognostic significance of HAVCR2 (TIM-3) in seminoma using an integrative approach combining transcriptomic analysis, penalized regression screen, and independent tissue-level validation.
METHODS: Elastic net-penalized Cox regression was applied to a four-gene immune checkpoint panel (HAVCR2, PDCD1, LAG3, TIGIT) in the TCGA seminoma cohort. Survival analyses were performed using progression-free interval (PFI). Findings were validated in an independent tissue microarray (TMA) cohort using immunohistochemistry. A pooled analysis integrating transcriptomic and protein-level data was conducted using a standardized biomarker approach.
RESULTS: HAVCR2 retained a relatively larger non-zero coefficient after penalization, whereas PDCD1, LAG3, and TIGIT were attenuated. In the TCGA cohort, higher HAVCR2 expression showed a trend toward improved PFI (log-rank p = 0.120). In the TMA cohort, high TIM-3 expression was associated with favorable relapse-free survival (log-rank p = 0.053), with all relapse events in the low-expression group. In the pooled cohort, HAVCR2/TIM-3 expression was associated with improved event-free survival (log-rank p = 0.019; HR = 0.201, p = 0.035); permutation-corrected p = 0.164, and findings are exploratory.
CONCLUSION: HAVCR2/TIM-3 expression demonstrates a consistent association with favorable clinical outcomes in seminoma across transcriptomic and protein-level analyses, with a lower risk of progression (HR = 0.201) in the pooled cohort. These exploratory findings support a potential prognostic role of TIM-3 reflecting an immune-active rather than exhausted microenvironment in seminoma, warranting prospective validation.
METHODS: Elastic net-penalized Cox regression was applied to a four-gene immune checkpoint panel (HAVCR2, PDCD1, LAG3, TIGIT) in the TCGA seminoma cohort. Survival analyses were performed using progression-free interval (PFI). Findings were validated in an independent tissue microarray (TMA) cohort using immunohistochemistry. A pooled analysis integrating transcriptomic and protein-level data was conducted using a standardized biomarker approach.
RESULTS: HAVCR2 retained a relatively larger non-zero coefficient after penalization, whereas PDCD1, LAG3, and TIGIT were attenuated. In the TCGA cohort, higher HAVCR2 expression showed a trend toward improved PFI (log-rank p = 0.120). In the TMA cohort, high TIM-3 expression was associated with favorable relapse-free survival (log-rank p = 0.053), with all relapse events in the low-expression group. In the pooled cohort, HAVCR2/TIM-3 expression was associated with improved event-free survival (log-rank p = 0.019; HR = 0.201, p = 0.035); permutation-corrected p = 0.164, and findings are exploratory.
CONCLUSION: HAVCR2/TIM-3 expression demonstrates a consistent association with favorable clinical outcomes in seminoma across transcriptomic and protein-level analyses, with a lower risk of progression (HR = 0.201) in the pooled cohort. These exploratory findings support a potential prognostic role of TIM-3 reflecting an immune-active rather than exhausted microenvironment in seminoma, warranting prospective validation.